Status:
UNKNOWN
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
Lead Sponsor:
Julius-Maximilians University
Conditions:
Malignant Melanoma
Pancreatic Cancer
Eligibility:
All Genders
19-90 years
Phase:
PHASE1
PHASE2
Brief Summary
This study evaluates the safety, the immunological response and the clinical outcome of a vaccination with survivin peptides for patients with advanced melanoma, pancreatic, colon and cervical carcino...
Detailed Description
As prognosis of advanced melanoma, pancreatic, colon and cervical cancer remains gloomy, new therapeutic modalities have to be developed to improve the patient´s clinical outcome. Immunotherapy, which...
Eligibility Criteria
Inclusion
- Advanced melanoma, pancreatic, colon and cervical cancer
- At least 1 prior postoperative conventional therapy (chemotherapy, radiation, immunotherapy)
- HLA-A1, -A2, -B35
- More than 4 weeks since last chemo-, immune- or radiotherapy
- ECOG-PS (Eastern Cooperative Oncology Group- Performance Status) of 0-1
- Sufficient renal, hepatic and bone marrow function: thrombocytes \> 75.000/ul; hb \> 9 g/dl; leucocytes \> 2.500/ul; creatinine \< 2 mg/dl; GOT/GPT \< twice the normal value
- negative for HIV and Hbs
- Older than 18 years
- Informed consent
Exclusion
- Acute/chronic infections
- Positive for HIV, Hbs
- Autoimmune disorders
- Pregnancy, breast feeding
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00108875
Start Date
April 1 2003
Last Update
July 28 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Julius-Maximilians-University of Wuerzburg, Germany, Department of Dermatology
Würzburg, Bavaria, Germany, 97080